PRHeartseed raises $26 Million in Series B Funding
Co-DevelopmentOur research partner, Keio Univ. applied for permission to conduct FIH of iPSC-derived CMs transplant to patients with DCM.
OtherKikuo Yasui was appointed as COO
OtherTomoyuki Kikugawa was appointed as External Auditor (full-time)
PRHeartseed Inc. was selected as one of the subsidy program of Japan Agency for Medical Research and Development (AMED), supporting Research Project for Practical Applications of Regenerative Medicine
PRAnnounced that 800 million yen was raised through third-party allocation of new shares from Angel Bridge, Astellas Venture Management and Shibuya Cooperation
PRAnnounced that 100 million yen was raised through third-party allocation of new shares from Angel Bridge